Providing a stable supply of high-quality pharmaceuticals and other products is an important duty of a pharmaceutical company.

We will strengthen our quality assurance and production systems to ensure uninterrupted access to reliable pharmaceuticals and other products for patients and medical institutions. 

We are also fully committed to managing risks associated with raw material procurement and taking preventive action against such risks.
 

• Manufacture and stably supply pharmaceuticals and other products of guaranteed quality by maintaining the quality management system compliant with global standards.
• Ensure a continuous supply of pharmaceuticals and other products through rigorous management of associated with raw material procurement and product supply.

1.    Engage in continuous GMP compliance activities (compliance with the GMP Ministerial Ordinance, manufacturing and marketing approval matters).  
2.    Foster a quality culture to ensure a stable supply of pharmaceuticals and other products of guaranteed quality.
3.    Enhance optimal inventory control of raw materials and products as well as preventive maintenance activities aimed at uninterrupted production.
 

• Conducted 22 audits (paper and on-site) of contract manufacturers, suppliers, and distributors
• Underwent regular audits by authorities in Japan and abroad. No serious issues noted. Addressed minor issues and guidance items
• Confirmed alignment with GMP and fostering of quality culture through regular management reviews
• Adopted performance indicators on each plant basis to foster culture of quality
• Identified issues in system building to achieve more sophisticated inventory control
   

• Progress with management reviews
• Progress with audits and audit responses
• Progress with fostering a quality culture
• Status of inventory availability based on production schedules
• Status of maintenance for quality assurance and stable production
• Progress with maintaining manuals to prepare against large-scale disasters
   

Enabling greater numbers of patients over a wider area to appropriately use pharmaceuticals and other products that address unmet medical needs is the mission of a pharmaceutical company. 

It is a mission of a pharmaceutical company to promote responsible use of pharmaceuticals and other products that address unmet medical needs to a greater number of patients. 

We are forging ahead with global expansion of pharmaceuticals and other products meeting medical needs. As a pharmaceutical manufacturer, we also strive to enhance information provision to expand appropriate recognition of the safety and efficacy of our pharmaceuticals and medical devices and of the diseases that our products treat.

• Provide pharmaceuticals and medical devices with high efficacy and safety to a greater number of patients.
• Appropriately provide information about the safety and efficacy of pharmaceuticals and medical devices as well as promoting their proper use.

1. Cooperate with sales partners to raise market awareness of existing products.
2. Accelerate global expansion of existing products and products in development.
3. Upgrade products in line with medical needs.
4.  Provide information of high medical and scientific value that contributes to post-marketing product development.
5. Enhance operation of disease awareness websites and informationprovision to the media.
6. Comply with post-marketing safety management standards, and gather, evaluate, and provide safety management information promptly and properly.

• Published three research papers and gave two academic presentations as part of evidence generation leading to drug fostering and evolution
• Built new evidence with eight joint-research collaborations related to post-marketing product development
• Held seminars and briefings in cooperation with sales companies and participated in exhibitions (16 co-sponsored seminars in Japan)
• Participated in media interviews and shared information on our website to inform physicians and educate the public about the disease
• Ran patient-focused campaigns in cooperation with sales companies
   

• Number of products shipped (pharmaceuticals and medical devices)
• Status of product improvement 
• Activities for providing information to improve product value 
• Number of views for disease awareness websites
• Hosting of media seminars, etc.
• Progress with educating about pharmacovigilance

Compliance is the foundation of corporate activities. Furthermore, pharmaceutical companies are required to have a higher sense of ethics and must comply with pharmaceutical industry guidelines and standards.

Seikagaku is managed to ensure that each individual employee not only complies with laws and regulations but also acts with high ethical standards. 

Additionally, business operations meeting society’s expectations are essential for sustainable corporate growth and enhancement in corporate value over the medium and long term. We are continuously working to develop a highly effective corporate governance system.

• All directors, officers, and employees follow the compliance program and act with strong compliance awareness.
• Develop an optimal corporate governance system in order to engage in decision making that is transparent and fair as well as quick and decisive.

1. Foster compliance awareness by periodically providing education about the Compliance Code of Conduct and other compliance related matters.
2. Establish internal and external consultation/whistleblowing channels and appropriately respond to any issues raised. 
3. Monitor the status of corporate governance by the Board and review the corporate governance system periodically.
4. Enhance provision of information to Outside Directors and Outside Audit & Supervisory Board Members; promote improvement activities based on the results of the effectiveness evaluations of the Board.
    

• Expanded the scope of application of sustainability-related polices to subsidiaries
• Submitted our Corporate Governance Report to comply with all principles in the Corporate Governance Code
• Made partial revisions to the SKK Group Compliance Code of Conduct (expanded provision concerning respect of human rights)
• Made partial revisions to compliance-related rules (added provision for establishing third-party committees for serious matters)
• Conducted Code of Conduct training, theme-based training, and an awareness survey to foster an awareness of compliance
• Held meetings with outside directors concerning initiatives for human capital management
   

• Progress with compliance education
• Usage of whistleblowing channel consultation and reporting desks
• Operational status of internal control systems
• Corporate Governance Code compliance 
• Information provision to outside directors
• Evaluations of the effectiveness of the Board of Directors and improvements activities
   

• Appropriate response to the Corporate Governance Code
• Evaluations of the effectiveness of the Board of Directors by all Board members and auditors, and its verification by outside directors

►Annual evaluation and verification

Results (Fiscal 2023)

• Maintained proper running of Board and other meetings as well as the internal control system for various committees
• Conducted a survey and evaluated effectiveness of outside directors in March and reported to the Board in April

The foundation for corporate growth is human resource management that secures and develops diverse human resources who prove valuable in business activities and that promotes their advancement.

We consider human resources to be an important corporate asset and develop human resources capable of creating new value. 

We are also supporting all employees with the environment, systems, and frameworks where they can fully demonstrate their capabilities, in order that their advancement becomes the driving force for our sustainable growth.
 

• Develop and retain autonomous employees who are able to achieve results proactively with a sense of passion and pride while improving their skills and building their careers.

1. Continuously revise personnel systems and improve treatment of senior and reemployed employees, which boosts employee motivation.
2. Engage in planned recruiting activities with diversity in mind, as well as assigning and training employees so that their diversity can fully contribute to our business activities.
3. Enhance structured education curriculum and implement training that take job rotation into consideration, in order to foster autonomous employees.
4. Promote work style reform and measures to improve work-life balance.
5. Enhance mental health care measures and health promotion activities in order to appropriately manage and promote employees’ physical and mental health.

• Conducted an employee engagement survey
• Shared a variety of human capital data in our disclosures, including information on growth opportunities and employment diversity
• Made continuous improvements to the training curriculum and enhanced feedback to managers about workers’ training status
• Adopted a working system and compensation designed to support increased production at plants and a stronger foundation, and enhanced recruiting
• Decided on in-house seminars in light of stress check results as part of efforts to promote employee health

• Changes to HR systems
• Percentages of women hired/currently employed
• Serving in managerial positions
• Percentages of mid-career employees hired/currently employed/serving in managerial positions
• Percentage of persons with disabilities hired
• Attrition rate (voluntary)
• Three-year retention rate of new graduate recruits
• Status of education and training for human resource development
• Status of work style reforms and initiatives to improve work-life balance
• Average number of days of paid leave taken
• Average monthly overtime hours number of overtime hours per month
• Number of employees taking childcare and nursing care leave (men and women, including contract employees) 
• Percentage of workers returning to work after childcare leave
• Implementation status of mental health care measures, etc.
   

• Percentage of women recruits

　　►Targeting 50%, annually

• Percentage of women in managerial positions

　　►Targeting at least 25% by end-March 2026

• Percentage of mid-career recruits

　　►Targeting 50%, annually

• Number of career training courses

　　►Targeting 15 or more per year
 

Results (Fiscal 2023)

• Percentage of female recruits: 25.4％
• Percentage of women in managerial positions: 17.4％
• Percentage of mid-career recruits: 67.8％
• Number of career training courses: 22 
   

The impacts of global warming and other environmental problems are apparent, and measures to protect the environment and preserve biodiversity have become a top priority for society. 
Responding to these problems is one of the business challenges that relates not only to risk reduction but also to profit opportunities.

As a member of society, we aim to maintain a balance between environmental protection and business growth and engage in business activities with a low environmental footprint, on top of complying with environmental laws and regulations.

• Contribute to the realization of a sustainable society by implementing measures for reducing environmental impact and climate change, and preserving biodiversity in our business activities.

1. Implement effective measures for energy use reduction.
2. Convert to energy sources that lead to CO2 emissions reduction.
3. Mitigate water pollution load by introducing equipment with low environmental impact for water preparation for manufacturing and for wastewater treatment.
4. Undertake biodiversity preservation activities, including a shift to non-animal-based products.

• Achieved continuous reduction in energy use (five-year average energy consumption rate of 97.5% / energy conservation evaluation*: Class S)
• Achieved a reduction in CO2 emissions (6.0% reduction from the previous year)
• Procured CO2-free electricity, successfully switching to non-fossil fuel energy at four sites in Japan
• Continued horseshoe crab release and conservation activities at a group company

*Energy conservation evaluation:
It classifies corporations based on the results of energy conservation (Class S/excellent, Class A/general, or Class B/stagnant).
Class S (≧1% reduction on average over 5 years) corporations are announced on the website of the Ministry of Economy, Trade, and Industry as excellent corporations.

• Energy use (crude oil equivalent) 
• CO2 emissions
• Progress with using renewable energy 
• Water pollution load (COD)
• Progress with shift to non-animal origin products 
• Progress with biodiversity preservation activities
   

• CO2 emissions (Non-consolidated）
  ►46% reduction by 2030（Scope 1and2 compared to FY2017）
  ►Aim to be carbon neutral by 2050
  ►Scope 3 calculations（disclose figures by 2025）

 
Results (Fiscal 2023)
Scope 1 and 2：21,368 t (18％ reduction compared to FY2017, market-based method)
Scope 3：68,393 t (estimate based on simplified calculation method)